Skip to main content

Table 5 Pathways in common in all breast cancer subtypes and specific for each subtype as derived from the proposed network approach

From: In silico identification of drug target pathways in breast cancer subtypes using pathway cross-talk inhibition

Common to all Luminal A Luminal B HER2 Basal
Assembly of RNA polymerase II complex Cell cycle regulation by BTG family proteins Antioxidant action of vitamin C Actin cytoskeleton signaling Aryl Hydrocarbon Receptor Signaling
Axonal guidance signaling Chemokine signaling Germ cell-sertoli cell junction signaling Adrenergic signaling eNOS signaling
Coagulation system Chondroitin sulfate biosynthesis HMGB1 signaling Breast cancer regulation by Stathmin1 Fatty acid oxidation I
Colorectal cancer metastasis signaling chondroitin sulfate biosynthesis (late stages) IL-6 signaling cAMP-mediated signaling Gluconeogenesis I
EIF2 signaling Ephrin B signaling Linolenate biosynthesis II (animals) Cardiac hypertrophy signaling Glycolysis I
Ethanol degradation II Granulocyte adhesion and diapedesis Antioxidant action of vitamin C Caveolar-mediated endocytosis signaling IL-1 signaling
Ethanol Degradation IV Heparan sulfate biosynthesis Germ cell-sertoli cell junction signaling Corticotropin Releasing Hormone Signaling Mitochondrial Dysfunction
Extrinsic prothrombin activation pathway Heparan sulfate biosynthesis (late stages) HMGB1_Signaling CREB signaling in neurons mTOR signaling
Fatty acid-oxidation LXR/RXR activation IL-6 signaling DNA damage-induced 14–3–3 signaling Phenylalanine Degradation IV (Mammalian, via Side Chain)
HIF1 signaling Pancreatic adenocarcinoma signaling Linolenate biosynthesis II (animals) Endothelin-1 signaling Phototransduction pathway
Histamine degradation Pregnenolone biosynthesis   Gap junction signaling PI3K/AKT signaling
Noradrenaline and adrenaline degradation Regulation of cellular mechanics by calpain protease   GDNF family ligand–receptor interactions  
Oxidative ethanol degradation III Semaphorin signaling in neurons   Glycine betaine degradation  
Putrescine degradation III Superoxide radicals degradation   Glycogen degradation II  
Tryptophan degradation X (mammalian, via tryptamine)    Induction of apoptosis by HIV1  
    Leptin signaling in obesity  
    Macropinocytosis signaling  
    NAD biosynthesis II (from tryptophan)  
    Ovarian cancer signaling  
    Relaxin signaling  
    RhoGDI signaling  
    Role of IL-17A in psoriasis  
    Role of tissue factor in cancer  
    Sperm motility  
    Synaptic long term depression  
    tRNA splicing  
    Tryptophan degradation to 2-amino-3-carboxymuconate semialdehyde  
    TWEAK Signaling  
  1. In italics pathways that are target of FDA-approved drugs for breast cancer are indicated
\